Growth factors for the liquid biopsy market growth include a growing prevalence of cancer, technological advancements in the field of cancer diagnostics, and a growing preference for minimally invasive cancer diagnostics. Moreover, ongoing research in liquid biopsy assays and tests, aided by the rising adoption and development of multi-cancer early detection tests, presents growth opportunities for the overall market.
One of the most advanced technologies related to genetic alterations and used for the detection of a tumor is liquid biopsy. It has been used in the stratification of the tumor, thereby offering targeted therapy to the cancer. For instance, the FDA approved, in January 2023, the liquid biopsy assay Guardant360 CDx by Guardant Health as a companion diagnostic to diagnose ESR1 mutant breast cancer. Recent inventions, progressions, and expansion in this sector boost liquid biopsy and foster market growth.
Global Liquid Biopsy Market size was valued at USD 7.6 billion in 2023 and is poised to grow from USD 8.75 billion in 2024 to USD 26.95 billion by 2032, growing at a CAGR of 15.1% during the forecast period (2025-2032).
Another critical growth opportunity for the global liquid biopsy market is provided by Multi Cancer Early Detection (MCED). The MCED market is an emerging sector of interest for the diagnostics industry as it allows the early detection of cancer and, consequently, the early treatment of such patients by saving time and minimizing the risk of such invasive medical surgical procedures. Some disadvantages of single cancer tests include high false-positive rates and optimized sensitivity.
Get a Free Sample PDF of the Report – https://www.skyquestt.com/sample-request/liquid-biopsy-market
The 2025 global Liquid Biopsy Market report provides a comprehensive analysis of key industry players, market trends, pricing structures, and competitive dynamics, offering insights into the market landscape from 2025 to 2032. As a rapidly evolving sector, the Liquid Biopsy Market drives economic growth, innovation, and technological advancements through the development, production, and distribution of products and services. This report highlights the market’s growth potential and its impact on global industries, providing valuable insights for stakeholders, investors, and policymakers.
Detailed Segmentation and Classification of the report (Market Size and Forecast – 2032, Y-o-Y growth rate, and CAGR):
The Liquid Biopsy Market can be segmented based on several factors, including product type, application, end-user, and distribution channel.
Global Liquid Biopsy Market is segmented by Product, Circulating Biomarker, Technology, Application, Clinical Application, Sample Type, End User and region.
Based on Product, the market is segmented into Assay Kits, Instruments and Services.
Based on Circulating Biomarker, the market is segmented into Circulating Tumor Cells, Circulating Tumor DNA, Cell-Free DNA, Extracellular Vesicles and Other Circulating Biomarkers.
Based on Technology, the market is segmented into Multi-Gene Parallel Analysis Using NGS and Single-Gene Analysis Using PCR.
Based on Application, the market is segmented into Cancer Applications and Non-Cancer Applications.
Based on Clinical Application, the market is segmented into Therapy Selection, Treatment Monitoring, Early Cancer Screening and Recurrence Monitoring.
Based on Sample Type, the market is segmented into Blood Samples and Other Sample Types.
Based on End User, the market is segmented into Reference Laboratories, Hospitals & Physician Laboratories, Academic & Research Centers and Other End Users.
Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.
Liquid Biopsy Market – Regional Analysis:
North America dominated the global liquid biopsy industry with a revenue share of almost 50.76% in 2024 due to high prevalence of cancer, rapid technological advancement, and increasing government initiatives. The market is also led by the U.S. because more investments and the presence of various biotechnology companies are developing advanced tests.
Liquid biopsy is being supported by various organizations such as the American Society of Clinical Oncology, and revenue is predicted to increase within this market. The size of the market will grow during the forecast period, driven by intense competition between biotechnology firms and governments’ increased investments in institutes about healthcare to develop more complex tests.
Top Market Players in Liquid Biopsy Market are:
F. Hoffmann-La Roche Ltd (Switzerland)
Thermo Fisher Scientific Inc. (US)
Illumina, Inc. (US)
Guardant Health, Inc. (US)
Biocept, Inc. (US)
Sysmex Corporation (Japan)
Natera, Inc. (US)
Biocartis Group NV (Belgium)
Bio-Rad Laboratories, Inc. (US)
OncoCyte Corporation (US)
Adaptive Biotechnologies Corporation (US)
Angle PLC (United Kingdom)
Epic Sciences, Inc. (US)
Neogenomics Laboratories (US)
CellMax Life (US)
Menarini-Silicon Biosystems (Italy)
Lunglife AI Inc. (US)
For a customized report, contact us to request personalization – https://www.skyquestt.com/speak-with-analyst/liquid-biopsy-market
Recent Developments in Liquid Biopsy Market:
In June 2022, F. Hoffmann-La Roche Ltd. collaborated with the Lung Cancer Research Foundation (LCRF) and Lung Cancer Mutation Consortium (LCMC) to participate in the LCMC 4th screening trial to evaluate actionable drivers in early-stage lung cancer for targeted therapy options in patients.
In May 2022, Guardant Health, Inc. announced that its blood-sample-based cancer testing services are now available at VHIO’s liquid biopsy testing facility in Barcelona, Europe.
In April 2022, Stilla Technologies and Promega Corporation have announced a strategic partnership to offer a comprehensive digital PCR workflow solution for a broad portfolio of applications in cancer research, including liquid biopsy, sentinel pathogen testing, among others.
Take Action Now: Secure Your Liquid Biopsy Market Today – https://www.skyquestt.com/buy-now/liquid-biopsy-market
Forward-Looking Insights
The Liquid Biopsy Market is set to experience sustained growth, fueled by technological advancements, broader global market access, and rising industry demand. With the industry addressing emerging challenges and capitalizing on new opportunities, it is expected to drive innovation and play a pivotal role in advancing global health and economic progress.
About Company:
SkyQuest is an IP focused Research and Investment Bank and Accelerator of Technology and assets. We provide access to technologies, markets and finance across sectors viz. Life Sciences, CleanTech, AgriTech, NanoTech and Information & Communication Technology.
We work closely with innovators, inventors, innovation seekers, entrepreneurs, companies and investors alike in leveraging external sources of R&D. Moreover, we help them in optimizing the economic potential of their intellectual assets. Our experiences with innovation management and commercialization have expanded our reach across North America, Europe, ASEAN and Asia Pacific.
Contact Details:
SkyQuest Technology Group
USA (+1) 351-333-4748
Email: [email protected]
